Business
CDX Antibody is Effective against AML in vivo
CDX Antibody is Effective against AML in vivo.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 1999B Hemogenyx Pharmaceuticals PLC 05 June 2019 \n\n \n \n \nHemogenyx Pharmaceuticals plc\n(\"Hemogenyx\" or the \"Company\")\n \nCDX Antibody is Effective against AML in vivo\n \n \nHemogenyx Pharmaceuticals plc (LSE: HEMO) announces the first data results from in vivo testing of its CDX bi-specific antibody (\"CDX antibody\") product candidate for the treatment of Acute Myeloid Leukemia (\"AML\"), a form of blood cancer. This follows the successful in vitro testing of the CDX antibody for the treatment of Acute Lymphoblastic Leukemia (\"ALL\") announced on 30 May 2019. \n \nThe first data results demonstrate that the CDX antibody is capable of eliminating a subset of AML cells in vivo. The CDX antibody was shown to target AML cells that overexpress the protein FLT3. The CDX antibody binds to the FLT3 protein that is located on the surface of unwanted (target) cells, binds to the CD3 protein on the surface of T-cells, and ultimately redirects T-cells to kill the target cells. The Company has verified the efficacy of CDX against AML in vivo, using its proprietary advanced hematopoietic chimeric (\"AHC\") mice (humanized mice).\n \nBackground on Acute Myeloid Leukemia\n \nAML affected about one million people globally in 2015 and resulted in 147,000 deaths. AML accounts for roughly 1.8% of cancer deaths in the United States with more than 20,000 new cases diagnosed in the US and 18,000 cases in Europe every year.\n \nDespite numerous advances in understanding the biology and pathogenesis of AML, treatment remains unsatisfactory. Relapsed or refractory (R/R) AML is nearly universally fatal. The only curative treatment is allogeneic hematopoietic stem cell transplantation (HSCT) with success rates less than 30% in the patients with chemo-sensitive disease. Unfortunately, most patients lack sensitivity to currently available therapies and therefore do not consider transplant or have extremely poor outcomes following allogeneic HSCT. The Directors believe that the Company's CDX antibody could replace traditional methods of treatment of relapsed/refractory AML. \n \nIt is estimated that the value of the global therapeutic market for AML was about $700M in 2018 and expected to grow to more than $1.5B by 2024.\n \nVladislav Sandler...